In vitro generation of influenza-specific polyfunctional CD4+ T cells suitable for adoptive immunotherapy

Cytotherapy

Volumn 14, Issue 2, 2012, Pages 182-193

  Gaundar, Shivashni S ^a   Blyth, Emily ^a   Clancy, Leighton ^a,b   Simms, Renee M ^a   Ma, Chun K K ^a   Gottlieb, David J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Adoptive immunotherapy; Immune reconstitution; Influenza virus specific T cells; Stem cell transplantation; T cell therapy

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BRISBANE VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IN VITRO STUDY; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; VIRUS;

EID: 84855892127     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.613932     Document Type: Article

References (40)

1. Kharfan-Dabaja MA, Velez A, Richards K, Greene JN, Field T, Sandin R. Infl uenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int J Hema-tol. 2010;91:124-7.
2. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant infl uenza A(H1N1) virus. Journal of the American Medical Assn. 2009;301:1042-6.
3. Raboni SM, Nogueira MB, Tsuchiya LRV, Takahashi GA, Pereira LA, Pasquini R, et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation. 2003;76:142-6. (Pubitemid 36880830)
4. Ljungman P, Avetisyan G. Infl uenza vaccination in hema-topoietic SCT recipients. Bone Marrow Transplant. 2008; 42:637-41.
5. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal infl uenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation. 2008;86:257-63.
6. Ferguson P, Jordens C, Gilroy N. Patient and family education in HSCT: improving awareness of respiratory virus infection and infl uenza vaccination. A descriptive study and brief intervention. Bone Marrow Transplant. 2009;45:656-61.
7. Tramontana AR, George B, Hurt AC, Doyle JS, Langan K, Reid AB, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis. 2010;16:1068-75.
8. Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, et al. Humoral and cellular immunity to primary H1N1 infection in patients with hematological malignancies and following stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:632-9.
9. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant infl uenza virus from immunocom-promised patients: a case series. J Infect Dis. 2006;193:760-4.
10. George B, Ferguson P, Kerridge I, Gilroy N, Gottlieb D, Hertzberg M. The clinical impact of infection with Swine fl u (H1N1 09) strain of infl uenza virus in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2010;17:147-53.
11. Martino R, Pi Òana J, Parody R, Valcarcel D, Sureda A, Brunet S, et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009;44:749-56.
12. Subbramanian RA, Basha S, Shata MT, Brady RC, Bernstein DI. Pandemic and seasonal H1N1 infl uenza hemagglutinin-specific T cell responses elicited by seasonal infl uenza vaccination. Vaccine. 2010;28:8258-67.
13. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 infl uenza virus. New Engl J Med. 2009;361: 1945-52.
14. Richards KA, Topham D, Chaves FA, Sant AJ. Cutting edge: CD4 T cells generated from encounter with seasonal infl u-enza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol. 2010; 185:4998-5002.
15. Tan P, Khan AM, August JT. Highly conserved infl uenza A sequences as T cell epitope-based vaccine targets to address the viral variability. Human Vacc. 2011;7:402-9.
16. Valkenburg SA, Rutigliano JA, Ellebedy AH, Doherty PC, Thomas PG, Kedzierska K. Immunity to seasonal and pandemic infl uenza A viruses. Microbes Infect. 2011;13:489-501.
17. Lee BO, Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Makris M, Sprague F, et al. CD4 T cell-independent antibody response promotes resolution of primary infl uenza infection and helps to prevent reinfection. J Immunol. 2005; 175:5827-38. (Pubitemid 41508067)
18. Wolniak KL, Shinall SM, Waldschmidt TJ. The germinal center response. Crit Rev Immunol. 2004;24:39-65. (Pubitemid 39655011)
19. Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, et al. Transfer of infl uenza vaccine-primed cos-timulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of infl uenza immunity: results of a randomized clinical trial. Blood. 2011;117:63-71.
20. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009;254:149-54.
21. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8 + T cells by a fl ow cytometric assay for degranulation. J Immunol Methods. 2003;281:65-78. (Pubitemid 37324571)
22. Harari A, Cellerai C, Enders FB, Kostler J, Codarri L, Tapia G, et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci USA. 2007;104:16233-8. (Pubitemid 350099390)
23. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4 + T cells endowed with proliferative capacity. J Exp Med. 2003;198:1909-22. (Pubitemid 38032123)
24. Seidel A, Smith D, Yung E, Aquino L, Srivastava T, Pullarkat V, et al. CD154 Expression is associated with neutralizing antibody titer levels postinfl uenza vaccination in stem cell transplant patients and healthy adults. Biol Blood Marrow Transplant. 2011;17:524-33.
25. Muller M, Blum H, Er F, Thimme R, Semmo N. Cellular immune response in hepatitis C infection: role of CD154 expression and clinical relevance. Deutsche Med Wochenschrift (1946). 2011;136:1073-7.
26. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4 + T cells with diverse cytokine profiles. Nature Med. [Res Support, NIH, Intramural]. 2005;11:1113-7. (Pubitemid 41486835)
27. Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, et al. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol. 2011;186:5556-68.
28. Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz J, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011;96:1231-5.
29. Tekgunduz E, Yuksel M, Erbay C, Aribas B, Ozdilekcan C, Arslan H, et al. Pandemic 2009 H1N1 infl uenza in patients with hematopoietic stem cell transplantation and hematologic malignancy: single center experience. Oncology. 2010;79: 409-14.
30. Wei JY, Chen FF, Jin J, Mai WY, Qian WB, Meng HT, et al. Novel infl uenza A (H1N1) in patients with hematologic disease. Leuk Lymph. 2010;51:2079-83.
31. Espinosa-Aguilar L Green JS, Forrest GN, Ball ED, Maziarz RT, Strasfeld L, et al. Novel H1N1 infl uenza in hematopoietic stem cell transplantation recipients: two centers'experiences. Biol Blood Marrow Transplant. 2011;17:566-73.
32. Nichols WG, Guthrie KA, Corey L, Boeckh M. Infl uenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39:1300-6. (Pubitemid 39458515)
33. Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, et al. Seroprotective titers against 2009-H1N1 infl uenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17:434-8.
34. de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96:307-14.
35. Mohty B, Bel M, Vukicevic M, Nagy M, Levrat E, Meier S, et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted infl uenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica. 2011;96:896-904.
36. Hanley PJ, Shaffer DR, Cruz CRY, Ku S, Zou BT, Liu H, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011;13:976-86.
37. Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia PJ. Generation of trispecific cytotoxic T cells recognizing cytome-galovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. J Immu-nother. 2007;30:544-56. (Pubitemid 46988088)
38. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Med. 2006;12: 1160-6. (Pubitemid 44527351)
39. Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V, et al. Prophylactic infusion of cytome-galovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic sstem cell transplantation. Blood. 2008;112: 3974-81.
40. Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, Rooney CM, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116:4700-2.